登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603112 证券简称：华翔股份 公告编号：2026-006 山西华翔集团股份有限公司关于 持股5%以上股东拟非公开发行可交换公司债券办理持有股份担保及信托登记的公告 2、中德证券已在中国证券登记结算有限责任公司开立了担保及信托专户，账户名为"山西交投一中德证 券一26晋交EB担保及信托财产专户"； 3、山西交投及中德证券将向中国证券登记结算有限责任公司申请在本次债券发行前办理担保及信托登 记，即将山西交投持有的共计16,722,409股华翔股份股票，约占公司已发行股本总数的3.10%，划入担 保及信托财产专户（具体数量基于办理担保及信托登记的前20个交易日华翔股份A股股票均价计算，以 实际办理情况为准）； 4、担保及信托财产将以中德证券名义持有，并以"山西交投一中德证券一26晋交EB担保及信托财产专 户"为证券持有人登记在公司证券持有人名册上； 5、在行使表决权时，中德证券将根据山西交投的意见办理，但不得损害本次可交换公司债券持有人的 利益。 截至本公告日，山西交投共持有公司股份45,375,000股，持股比例为8.40%。本次担保及信托登记完成 ...

Core Viewpoint - Shanxi Jiaotou, a shareholder holding more than 5% of Huaxiang Co., has received approval from the Shanghai Stock Exchange for the non-public issuance of technology innovation exchangeable bonds not exceeding 200 million yuan [1] Group 1 - The bond issuance will be secured by stocks and trust, with Shanxi Jiaotou planning to transfer 16,722,409 shares of Huaxiang Co. (approximately 3.10% of the total issued capital) into a dedicated account for collateral and trust [1] - As of the announcement date, Shanxi Jiaotou holds 8.40% of Huaxiang Co.'s shares, which will decrease to 5.30% after the registration is completed, while maintaining a holding of 3.10% through the dedicated account [1] - The transaction does not affect the controlling rights of Shanxi Jiaotou and does not constitute a mandatory tender offer [1]

Core Viewpoint - The stock price of Huaxiang Co., Ltd. has increased by 1.67% to 17.66 yuan as of January 9, 2026, with a market capitalization of 9.539 billion yuan, ranking 6th in the home appliance components sector and 2117th in the A-share market [1]. Group 1: Company Announcements - The company announced the continuation of using up to 55 million yuan of idle convertible bond fundraising for cash management, with an authorization period of 12 months [1]. - No new financial products were purchased or redeemed between December 1 and December 31, 2025, with a maximum single-day investment in government bond reverse repos reaching 163.933 million yuan and total earnings of 1.659 million yuan over the past 12 months [1]. - As of the reporting period, the company has utilized 34.554 million yuan of its financial management quota, leaving a remaining quota of 20.446 million yuan [1]. Group 2: Shareholder Activities - The company’s shareholder, Shanxi Transportation Development Investment Group Co., Ltd., received a no-objection letter from the Shanghai Stock Exchange to issue up to 200 million yuan of exchangeable bonds aimed at professional investors, which will be listed on the exchange [1]. - The bond issuance will be underwritten by Zhongde Securities Co., Ltd. and will be conducted in installments, required to be completed within 12 months [1]. - As of the announcement date, Shanxi Transportation holds 45,375,000 shares of the company, accounting for 8.40% of the total share capital [1].

Core Viewpoint - Huabang Health (002004) is actively engaging in financial maneuvers, including a non-public issuance of convertible bonds and increasing its credit lines, to manage its debt and enhance operational liquidity [2][7]. Trading Information Summary - As of December 23, 2025, Huabang Health's stock closed at 4.83 yuan, down 0.62%, with a turnover rate of 1.01%, trading volume of 190,000 shares, and a transaction value of 91.92 million yuan [1]. - On the same day, the net inflow of funds from major investors was 446,680 yuan, while retail investors experienced a net outflow of 491,300 yuan [1]. Company Announcements Summary - The company announced a non-public issuance of convertible bonds not exceeding 1 billion yuan, with a term of up to 3 years, aimed at repaying interest-bearing debts [2]. - The board approved the application for a total credit line of up to 13.154 billion yuan for 2026, with a guarantee limit of 10.274 billion yuan [7]. - The company plans to conduct forward foreign exchange settlement and RMB foreign exchange options trading in 2026, with a total transaction limit of up to 41 million USD to mitigate exchange rate risks [5][6]. Related Transactions Summary - The company approved an increase in expected daily related transactions for 2025, totaling approximately 138.18 million yuan, and for 2026, expected related transactions amount to 1.199 billion yuan, involving multiple related parties [4]. - The pricing of related transactions will be based on market fair prices to ensure the company's independence [4]. Internal Control and Governance Summary - The company revised its independent director work system to ensure independence and proper governance, emphasizing the need for independent opinions on related transactions [7]. - The company has established a management system for the use of raised funds, ensuring that funds are used specifically for designated purposes and not for financial investments [8]. - The company has implemented a decision-making system for related transactions, detailing approval processes and disclosure requirements [9].

Core Viewpoint - Huabang Health (002004) is planning a non-public issuance of technology innovation exchangeable bonds to raise up to 1 billion RMB for debt repayment and other legal purposes [1] Group 1: Stock Performance - As of December 23, 2025, Huabang Health closed at 4.83 RMB, down 0.62% from the previous trading day [1] - The stock opened at 4.85 RMB, reached a high of 4.88 RMB, and a low of 4.81 RMB, with a trading volume of 91.92 million RMB and a turnover rate of 1.01% [1] Group 2: Bond Issuance - The company’s board approved a plan for a non-public issuance of technology innovation exchangeable bonds, targeting professional institutional investors [1] - The bond issuance will not exceed 1 billion RMB and will have a term of no more than 3 years, with the option to exchange for shares of Shandong Kaisheng New Materials Co., Ltd. [1] - The raised funds, after deducting issuance costs, will be used for repaying interest-bearing debts and other purposes compliant with legal regulations [1] - The issuance plan is subject to approval by the shareholders' meeting [1]

Core Viewpoint - Huabang Health (002004.SZ) has announced the approval of several proposals regarding the issuance of non-public technology innovation exchangeable corporate bonds, which will be submitted for shareholder meeting review [1] Group 1: Bond Issuance Details - The company plans to issue exchangeable corporate bonds that can be exchanged for shares of Shandong Kaisheng New Materials Co., Ltd. (stock code: 301069.SZ) [1] - The total scale of the bond issuance is not to exceed 1 billion RMB (including 1 billion RMB), which can be issued in one go or in multiple phases [1] - The specific issuance scale and timing will be determined by the board of directors based on the company's funding needs and market conditions, with authorization from the shareholder meeting [1] Group 2: Board Meeting Resolutions - The fourth meeting of the ninth board of directors reviewed and approved the proposals related to the bond issuance [1] - The proposals include the conditions for the non-public issuance of technology innovation exchangeable corporate bonds and the authorization for the board to handle related matters [1]

Core Viewpoint - Huabang Health (002004.SZ) has announced the approval of several proposals regarding the issuance of non-public technology innovation exchangeable corporate bonds, which will be submitted for shareholder meeting review [1] Group 1: Bond Issuance Details - The company plans to issue exchangeable corporate bonds targeting professional institutional investors, with a total scale not exceeding 1 billion RMB (including 1 billion RMB) [1] - The bonds will be exchangeable for shares of Shandong Kaisheng New Materials Co., Ltd. (stock code: 301069.SZ) [1] - The specific issuance scale and timing will be determined by the board of directors based on the company's funding needs and market conditions, with authorization from the shareholder meeting [1] Group 2: Board Meeting Resolutions - The fourth meeting of the ninth board of directors reviewed and approved the proposals related to the bond issuance [1] - The proposals include the conditions for the issuance of the exchangeable bonds and the authorization for the board to handle related matters [1]

Core Viewpoint - During the "14th Five-Year Plan" period, the capital market's ability to serve the real economy has been continuously enhanced, with Southwest Securities playing a crucial role as a service provider and facilitator for economic development [1][2]. Group 1: Service to the Real Economy - Southwest Securities has actively participated in various financial services, including corporate listings, financing, mergers and acquisitions, and risk management, significantly supporting local industrial upgrades and economic structure optimization [2]. - The company served as an independent financial advisor for Guangdong Songfa Ceramics Co., Ltd.'s major asset restructuring, which was the first approved cross-industry merger project since the release of the "merger six guidelines" [2]. - From 2021 to June 2025, Southwest Securities has cumulatively served over 260 billion yuan, with over 95 billion yuan specifically for the Chengdu-Chongqing economic circle, exceeding its "14th Five-Year Plan" targets ahead of schedule [3][4]. Group 2: Regional Economic Development - Southwest Securities has signed strategic cooperation agreements with 22 districts and counties in Chongqing, providing investment and risk management services exceeding 54 billion yuan [4]. - The company has engaged with 33 key state-owned enterprises in Chongqing, offering comprehensive services in mergers, bonds, and capital operations totaling over 6 billion yuan [4]. - The firm has initiated a "Walk into Listed Companies" campaign, providing over 16 billion yuan in financing services to listed companies in Chongqing [4]. Group 3: Business Growth and Innovation - In the first half of the year, Southwest Securities saw a 40-fold increase in new customer accounts compared to the previous year, indicating significant growth in its brokerage business [7]. - The company has successfully issued multiple asset-backed securities (ABS) products, totaling over 3 billion yuan, showcasing its strength in asset securitization [7]. - The firm has implemented digital transformation initiatives, reducing customer onboarding times significantly and enhancing compliance efficiency [7][8]. Group 4: Future Outlook - Southwest Securities aims to enhance its service capabilities through a multi-level cooperation system, focusing on tailored services for different regions and enterprises [5]. - The company is committed to high-quality development, continuously improving its core competitiveness across various business segments, including securities and futures brokerage, investment banking, and asset management [6][8]. - The firm plans to fully implement new development concepts and contribute more significantly to the real economy's growth [8].

Core Viewpoint - The report highlights the financial performance of Huabong Life Health Co., Ltd. for the first half of 2025, showing an increase in revenue and net profit compared to the same period last year. Financial Performance - Operating revenue for the reporting period reached CNY 5,945,032,088.09, a slight increase of 0.39% from CNY 5,922,042,354.85 in the previous year [1]. - Net profit attributable to shareholders was CNY 388,455,625.50, representing a significant increase of 23.90% from CNY 313,522,665.65 [1]. - The net profit after deducting non-recurring gains and losses was also reported, but specific figures were not provided [1]. - The net cash flow from operating activities increased by 46.10% to CNY 536,502,508.00 from CNY 367,219,592.32 [1]. - Basic and diluted earnings per share rose to CNY 0.1969, up 24.15% from CNY 0.1586 [1]. Asset and Equity Position - Total assets at the end of the reporting period were CNY 29,654,478,331.32, a 0.69% increase from CNY 29,450,469,334.61 at the end of the previous year [2]. - Net assets attributable to shareholders increased by 4.41% to CNY 9,748,372,423.62 from CNY 9,337,058,173.60 [2]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 73,829 [2]. - The largest shareholder, Chongqing Huabong Zhuoyuan Technology Co., Ltd., holds 18.71% of the shares [2]. - The report indicates that there were no changes in the controlling shareholder or actual controller during the reporting period [6]. Debt and Financial Ratios - The debt-to-asset ratio at the end of the reporting period was 46.17%, down from 47.46% [4]. - The EBITDA interest coverage ratio improved to 9.17 from 7.07 in the previous year [4].

Core Viewpoint - The announcement details a decrease in the shareholding percentage of the controlling shareholder, China Aerospace Science and Technology Corporation, from 84.27% to 83.99% due to the conversion of exchangeable bonds, without triggering mandatory tender offer obligations [1][2]. Group 1: Shareholding Changes - The controlling shareholder, China Aerospace Science and Technology Corporation, directly held 3,156,449,883 shares before the change [1]. - After the conversion of exchangeable bonds, the total shareholding of the controlling shareholder decreased to 83.99% [1]. - The change in shareholding does not violate any prior commitments or plans [1]. Group 2: Shareholder Information - The announcement confirms that the controlling shareholder and its concerted actors provided accurate and complete information regarding the shareholding changes [1]. - The concerted actors include China Academy of Launch Vehicle Technology and China Academy of Space Technology, which did not change their shareholding [1]. - The total number of shares held by the controlling shareholder and its concerted actors before the change was 355,971,240.7 shares, representing 84.27% [2]. Group 3: Bond Conversion Impact - The decrease in shareholding percentage is attributed to the conversion of exchangeable bonds issued in August 2024 [1]. - The company will monitor the conversion situation of the exchangeable bonds and fulfill its information disclosure obligations as required [2]. - The announcement clarifies that the shareholding change does not affect the status of the controlling shareholder or actual controller [2].